文献速递白血病造血干细胞移植与细胞治疗

伊达比星联合白消安环磷酰胺方案对比白消安环磷酰胺方案用于首次完全缓解中危急性髓系白血病自体造血干细胞移植:一项开放标签、多中心、随机3期试验

Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
PubMed 文献 · Am J Hematol · 2023-01-01

该随机前瞻性3期研究纳入154例首次完全缓解的中危急性髓系白血病患者,随机接受IDA-BuCy或BuCy预处理后行自体造血干细胞移植。两组2年复发率、总生存和无病生存均无显著差异,但IDA-BuCy组3级及以上方案相关毒性显著更高(28.9%对12.0%,p=0.015)。结论认为IDA-BuCy抗白血病活性与BuCy相似但毒性更高,选择时需谨慎。

要点

  • IDA-BuCy组3级及以上方案相关毒性发生率为28.9%,显著高于BuCy组的12.0%(p=0.015)。
  • 两组2年复发率分别为15.6%和19.5%(p=0.482),无显著差异。
  • 两组2年总生存(81.8%对83.1%,p=0.798)和无病生存(76.6%对79.2%,p=0.693)均无显著差异。

核心结论

  • 在首次完全缓解的中危急性髓系白血病自体造血干细胞移植患者中,IDA-BuCy较BuCy方案相关毒性更高,抗白血病活性相似。
  • 作者认为选择IDA-BuCy用于此类患者时需谨慎。

研究设计与样本

  • 随机前瞻性3期研究,共纳入154例首次完全缓解的中危急性髓系白血病患者,随机分配至IDA-BuCy组或BuCy组。
  • IDA-BuCy方案:伊达比星15 mg/m2/天,第-12至-10天;白消安3.2 mg/kg/天,第-7至-4天;环磷酰胺60 mg/kg/天,第-3至-2天。
  • 试验注册号ClinicalTrials.gov NCT02671708,已完成。

主要发现

  • 2年复发率:IDA-BuCy组15.6% vs BuCy组19.5%(p=0.482)。
  • 2年总生存率:IDA-BuCy组81.8% vs BuCy组83.1%(p=0.798)。
  • 2年无病生存率:IDA-BuCy组76.6% vs BuCy组79.2%(p=0.693)。
  • 3级及以上方案相关毒性:IDA-BuCy组76例中22例(28.9%) vs BuCy组75例中9例(12.0%)(p=0.015)。
  • 100天内结局为死亡的不良事件:IDA-BuCy组4例(5.3%) vs BuCy组0例。

临床怎么用

  • 作者认为,对于首次完全缓解的中危急性髓系白血病患者行自体造血干细胞移植时,选择IDA-BuCy需谨慎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a randomized prospective phase 3 study, designed to evaluate the efficacy and tolerability of idarubicin plus busulfan and cyclophosphamide (IDA-BuCy) versus BuCy in autologous hematopoietic stem-cell transplantation (auto-HSCT) for intermediate-risk acute myeloid leukemia (IR-AML) patients in first complete remission (CR1). One hundred and fifty-four patients were enrolled and randomized to receive IDA-BuCy (IDA 15 mg/m2/day on days -12 to -10, Bu 3.2 mg/kg/day on days -7 to -4, and Cy 60 mg/kg/day on days -3 to -2) or BuCy. The 2-year incidence of relapse was 15.6% and 19.5% in IDA-BuCy and BuCy groups (p = 0.482), respectively. There was no significant overall survival (OS) and disease-free survival (DFS) benefit for IR-AML patients receiving IDA-BuCy (2-year OS 81.8% in IDA-BuCy vs. 83.1% in BuCy, p = 0.798; 2-year DFS 76.6% in IDA-BuCy vs. 79.2% in BuCy, p = 0.693). Grade 3 or worse regimen-related toxicity (RRT) was reported for 22 (28.9%) of 76 and 9 (12.0%) of 75 patients in two groups (p = 0.015), respectively. AEs within 100 days with an outcome of death were reported for 4 (5.3%) and 0 patients in two groups. In conclusion, IDA-BuCy has higher RRT and similar anti-leukemic activity compared with BuCy in IR-AML patients in CR1 undergoing auto-HSCT. Thus, caution should be taken when choosing IDA-BuCy for IR-AML patients in CR1 with auto-HSCT. This trial is registered with ClinicalTrials.gov, NCT02671708, and is complete.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Liu H, Huang F, Zhang Y, et al. Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial. Am J Hematol. 2023. PMID: 36588387. doi:10.1002/ajh.26800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。